Document Detail


Is streptokinase useful in the treatment of deep vein thrombosis?
MedLine Citation:
PMID:  1251775     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Because of its fibrinolytic action, streptokinase is believed to reduce the severity of the postthrombotic syndrome in patients with deep vein thrombosis. A prospective and a retrospective study have been undertaken in an attempt to determine when this therapy is useful for patients with deep vein thrombosis. The prospective study included 15 patients with deep vein thrombosis: 5 were treated in the hospital with streptokinase and heparin and 5 only with heparin, 5 were treated at home with only phenprocoumon. All the patients received oral anticoagulant therapy for at least 6 months. Three to four months after the acute episode, phlebography and venous pressure measurements were carried out. Streptokinase appeared to give the best results but with more side-effects. In the retrospective study, 51 patients who had had deep vein thrombosis in 1969 were reexamined 31-47 months later. It was found that more than 50% of the patients with a thrombosis in the femoral and/or iliac vein developed a severe postthrombotic syndrome, in contrast to only 9% of those with a thrombosis in the popliteal vein or lower. It is recommended, on the basis of both the prospective and the retrospective study, that patients with a thrombosis in the femoral and/or iliac vein should be treated with either heparin or streptokinase during the early stage. It is probable that streptokinase will significantly decrease the frequency and severity of the postthrombotic syndrome in these patients in particular, although this has not yet been proven.
Authors:
R Bieger; R J Boekhout-Mussert; F Hohmann; E A Loeliger
Related Documents :
7799025 - Complications of indwelling venous access devices in cancer patients.
10505325 - Venous thromboembolism, factor v leiden, and methylenetetrahydrofolate reductase in a s...
21354855 - Oral brush biopsy analysis by matrix assisted laser desorption/ionisation-time of fligh...
17764535 - Quality of life after indefinite diversion/pouch excision in ileal pouch failure patients.
23372355 - Diagnostic value of afp-l3 and pivka-ii in hepatocellular carcinoma according to total-...
25366205 - Subclinical atherosclerosis in patients with rheumatoid arthritis by utilizing carotid ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Acta medica Scandinavica     Volume:  199     ISSN:  0001-6101     ISO Abbreviation:  Acta Med Scand     Publication Date:  1976  
Date Detail:
Created Date:  1976-04-10     Completed Date:  1976-04-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0370330     Medline TA:  Acta Med Scand     Country:  SWEDEN    
Other Details:
Languages:  eng     Pagination:  81-8     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Female
Fibrinogen / analysis
Follow-Up Studies
Heparin / therapeutic use
Humans
Male
Middle Aged
Phenprocoumon / therapeutic use
Prospective Studies
Retrospective Studies
Streptokinase / therapeutic use*
Thrombin / analysis
Thrombophlebitis / blood,  drug therapy*
Chemical
Reg. No./Substance:
435-97-2/Phenprocoumon; 9001-32-5/Fibrinogen; 9005-49-6/Heparin; EC 3.4.-/Streptokinase; EC 3.4.21.5/Thrombin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Enzymes and long-term survival after first myocardial infarction.
Next Document:  Streptokinase treatment of deep venous thrombosis of the lower extremity. Clinical, phlebographic an...